Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
about
Large granular lymphocytosis during dasatinib therapyChronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profileThe analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsAnti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia modelDasatinib promotes Th1-type responses in granzyme B expressing T-cellsOncogene withdrawal engages the immune system to induce sustained cancer regression.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyModeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitorsPretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeDiscovery of somatic STAT5b mutations in large granular lymphocytic leukemia.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia.Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicityLarge granular lymphocytic leukaemia pathogenesis and management.Immunomodulatory effects of anti-angiogenic drugs.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.Evolution of therapies for chronic myelogenous leukemia.Biological therapy and the immune system in patients with chronic myeloid leukemia.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Novel immune modulators used in hematology: impact on NK cellsChronic myeloid leukemia: overview of new agents and comparative analysis.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Immunology and immunotherapy of chronic myeloid leukemia.Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations.Sarcoma immunotherapy: past approaches and future directions.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection.Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy.Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
P2860
Q27012699-D88E7848-6FFB-4238-B851-2B5AE5597255Q28476476-12E8B35D-DCAF-46E4-B652-C10A5327D4EDQ30303161-CA65458D-6DA4-43B7-8C6C-0F87C8275084Q33397085-198D87DD-BE96-4077-B0D0-525D9ABD49D9Q33404602-84BC0F2D-DA58-47A4-9C5F-F2730613AF5FQ33798573-C94ECD82-9DF2-44C2-83C2-4111CE6BF080Q33815423-6119A2FE-02DB-43DB-AE38-70076F4F9846Q33930605-D9E8D570-1083-4FF0-9C41-07BBB21CABC2Q33987633-077761A4-0849-4718-928E-1010F20E50EDQ34361976-7AB41239-65C7-4457-BF45-E00EB166B7A0Q34451624-ADADD4AF-48DC-4B3F-8D98-2C1F912BF1E8Q35044993-7459523F-D8D0-44BA-8194-0D823F961396Q35194464-2A864741-2A3F-4545-B1DF-35CAEAA43A7BQ35804757-1E53F31F-2874-4889-B132-AC873FBD61CBQ36059184-31265A0C-8D3B-439F-9713-AC79E82602A9Q36889731-1CA68FA1-BECA-47DC-8164-DDC96FC9C673Q37098840-7510109A-A0A8-46D4-A8DC-8CA6EA99C13EQ37288036-E2A2E65F-F1DE-47D8-B8E1-E3860FC2E06FQ37352396-FEFCABD1-D85E-4215-BEB5-761D628F3214Q37821049-2BD5E2EA-8A7F-48BA-9F7D-49AFB5CF1B60Q37847051-C8635606-1D7E-468E-BB76-229AC0960A7CQ37918304-CEC187AF-8E2F-4E59-B823-CBC45CB4D6A3Q37966915-528385AF-DB8A-4C3E-816D-271C3923CB4DQ38015742-BC766A9F-94ED-490C-A67A-9812AEBF37C5Q38044753-3CFC9632-E87E-484D-B571-05DE076DC17BQ38073760-74E3F714-28C8-44A8-800A-DB1F5BDF4FB4Q38097728-97FB9469-40BB-433C-94CD-0639C8C4BD19Q38128723-F29306CF-7C20-438E-90B6-082E6264C5A8Q38175864-CA409C22-6077-4BBF-AFCF-BBA72B0A5E34Q38186800-03FBB6BC-FE98-4C0C-880A-C4198F8FC313Q38207986-5B884B8B-3A35-42AB-A0BA-3E691105F50CQ38866390-2AB39F72-A140-4CC8-AD6F-6473D8797C70Q39070576-BFA36417-B8F8-42B4-81B6-1A26A8334F04Q39226064-1001186C-F706-4FF5-AC1B-E58137A92DDAQ39379461-B1EC80B3-CF0D-4ADD-81C4-FBE59AB63900Q40196834-294196EF-FBB4-4B64-B744-FBF61AAEEAF1Q40297565-DEA40DC6-1A73-49FE-AFB9-FFE3C040B39EQ40679442-DAE2BE7A-227D-4AD6-9CFC-1AAC578024ECQ40807169-D57CD9F9-3E77-40E3-ACA2-0F1D99F022F9Q40877367-65A5B61B-ECA2-40D7-9EDD-86344A661D52
P2860
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Mono/oligoclonal T and NK cell ...... pand during dasatinib therapy.
@en
Mono/oligoclonal T and NK cell ...... pand during dasatinib therapy.
@nl
type
label
Mono/oligoclonal T and NK cell ...... pand during dasatinib therapy.
@en
Mono/oligoclonal T and NK cell ...... pand during dasatinib therapy.
@nl
prefLabel
Mono/oligoclonal T and NK cell ...... pand during dasatinib therapy.
@en
Mono/oligoclonal T and NK cell ...... pand during dasatinib therapy.
@nl
P2093
P50
P1433
P1476
Mono/oligoclonal T and NK cell ...... xpand during dasatinib therapy
@en
P2093
Leif Stenke
Marja Ekblom
Ruth Seggewiss
Veli Kairisto
Vesa Juvonen
P304
P356
10.1182/BLOOD-2009-12-256800
P407
P577
2010-04-22T00:00:00Z